Anavex Life Sciences Corp.

As of June 30, 2026, Anavex Life Sciences Corp. carries a market capitalization of 242.31M, placing it among publicly traded companies globally. Its enterprise value stands at 123.98M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Anavex Life Sciences Corp.'s next confirmed earnings release is scheduled for November 30, 2026.

As of June 30, 2026, Anavex Life Sciences Corp. has 92.70M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Anavex Life Sciences Corp. maintains a current ratio of 15.62, meaning it holds 15.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Anavex Life Sciences Corp. posted a negative return on equity (ROE) of -12.80, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -11.70, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 34.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Anavex Life Sciences Corp. recorded 18,000.00 in income tax expense. The company reported a pretax loss of -13.00M and -13.02M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Anavex Life Sciences Corp.'s stock has declined approximately 85.21% over the past 52 weeks. The 50-day moving average sits at 2.39, while the 200-day moving average is 3.20.

Over the twelve months ended June 30, 2026, Anavex Life Sciences Corp. generated - - in revenue and converted that into -13.02M in net income, yielding earnings per share of -0.14. EBITDA reached -17.37M, while operating income came in at -17.95M.

These figures are as of June 30, 2026. Total book value stands at 112.45M, with working capital of 112.45M providing operational flexibility.

Anavex Life Sciences Corp. produced -29.29M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -12.43: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -19.17, meaning Anavex Life Sciences Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Anavex Life Sciences Corp.'s most recent stock split took place on October 7, 2015 with a 4:1 split ratio.

As of June 30, 2026, Anavex Life Sciences Corp. has an Altman Z-Score of 15.04, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.